ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 235,91
-0,79%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) Actualités

KZIA Kazia Therapeutics Ltd

0,3887
0,01875 (5,07%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Kazia Therapeutics Ltd KZIA NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,01875 5,07% 0,3887 23:25:32
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,3646 0,357 0,389 0,37 0,36995
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
21/3/202413:52PRNUSKazia Therapeutics licenses paxalisib to Sovargen for..
13/3/202413:00PRNUSKazia announces presentation of new data at AACR Annual..
21/2/202422:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/2/202415:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202413:30PRNUSKazia Therapeutics Reports Early Conclusion of Clinical..
14/2/202421:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202400:35EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
05/2/202422:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/1/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202413:30PRNUSKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
12/1/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/12/202323:26EDGAR2Form F-3 - Registration statement by foreign private issuers
06/12/202314:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/12/202300:02PRNUSKazia Therapeutics Announces Closing of $2 Million..
04/12/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/12/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202314:00PRNUSKazia Therapeutics Announces $2 Million Registered Direct..
29/11/202322:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202322:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202313:01PRNUSKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE..
21/11/202313:30PRNUSKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS..
20/11/202322:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202322:30PRNUSKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
15/11/202315:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/11/202314:30PRNUSKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY..
10/11/202313:01PRNUSKAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS..
01/11/202321:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202312:01PRNUSKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING..
26/10/202313:56EDGAR2Form 20-F - Annual and transition report of foreign private..
23/10/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM..
13/10/202322:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202313:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202313:01PRNUSKazia announces voluntary delisting from ASX
10/10/202321:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING..
29/9/202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING..
29/9/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202313:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/7/202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/7/202313:00PRNUSKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA..
08/6/202313:00PRNUSKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO..
25/5/202313:01PRNUSKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE..

Dernières Valeurs Consultées

NASDAQ
KZIA
Kazia Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés